As of 2024-12-11, the Relative Valuation of Celldex Therapeutics Inc (CLDX) is (64.57) USD. This relative valuation is based on P/E multiples. With the latest stock price at 26.51 USD, the upside of Celldex Therapeutics Inc based on Relative Valuation is -343.6%.
The range of the Relative Valuation is (65.87) - (73.11) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.4x - 45.2x | 35.0x |
| Forward P/E multiples | 19.9x - 31.5x | 20.6x |
| Fair Price | (65.87) - (73.11) | (64.57) |
| Upside | -348.5% - -375.8% | -343.6% |
| Date | P/E |
| 2024-12-09 | -11.37 |
| 2024-12-06 | -11.53 |
| 2024-12-05 | -11.22 |
| 2024-12-04 | -11.44 |
| 2024-12-03 | -11.29 |
| 2024-12-02 | -11.72 |
| 2024-11-29 | -11.81 |
| 2024-11-27 | -12.01 |
| 2024-11-26 | -11.52 |
| 2024-11-25 | -12.12 |
| 2024-11-22 | -11.63 |
| 2024-11-21 | -11.29 |
| 2024-11-20 | -11.37 |
| 2024-11-19 | -10.76 |
| 2024-11-18 | -10.04 |
| 2024-11-15 | -10.14 |
| 2024-11-14 | -11.08 |
| 2024-11-13 | -11.56 |
| 2024-11-12 | -11.63 |
| 2024-11-11 | -11.29 |
| 2024-11-08 | -11.29 |
| 2024-11-07 | -11.40 |
| 2024-11-06 | -11.90 |
| 2024-11-05 | -10.95 |
| 2024-11-04 | -10.93 |
| 2024-11-01 | -11.06 |
| 2024-10-31 | -11.22 |
| 2024-10-30 | -11.34 |
| 2024-10-29 | -11.56 |
| 2024-10-28 | -12.04 |
| 2024-10-25 | -11.60 |
| 2024-10-24 | -12.11 |
| 2024-10-23 | -12.34 |
| 2024-10-22 | -12.38 |
| 2024-10-21 | -12.35 |
| 2024-10-18 | -12.16 |
| 2024-10-17 | -12.37 |
| 2024-10-16 | -12.80 |
| 2024-10-15 | -12.66 |
| 2024-10-14 | -13.04 |
| 2024-10-11 | -13.49 |
| 2024-10-10 | -12.78 |
| 2024-10-09 | -12.96 |
| 2024-10-08 | -13.15 |
| 2024-10-07 | -13.09 |
| 2024-10-04 | -13.20 |
| 2024-10-03 | -13.28 |
| 2024-10-02 | -13.01 |
| 2024-10-01 | -13.95 |
| 2024-09-30 | -14.63 |